Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib plus recombinant human endostatin versus gefitinib alone for first-line EGFR-mutant advanced NSCLC
ChiCTR2000039905Phase 4Recruiting
- Sponsor
- Chengdu Fifth People's Hospital
- Start
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of gefitinib and endostar in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC) (2 arms), sponsored by Chengdu Fifth People's Hospital. Primary endpoint: Progression-free survival. Started Nov 2020; status: recruiting.
02
Drugs
gefitinibendostar
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000039905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039905.